Equities

Noxopharm Ltd

Noxopharm Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.11
  • Today's Change0.01 / 10.00%
  • Shares traded99.78k
  • 1 Year change+175.00%
  • Beta0.8868
Data delayed at least 20 minutes, as of Sep 20 2024 06:47 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

  • Revenue in AUD (TTM)2.41m
  • Net income in AUD-3.58m
  • Incorporated2015
  • Employees1.00k
  • Location
    Noxopharm LtdSuite 71, 159 Ridgecrop DriveCASTLE HILL 2154AustraliaAUS
  • Phone+61 29144-2223
  • Fax+61 29199-9600
  • Websitehttps://www.noxopharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medlab Clinical Ltd366.64k-3.94m15.04m14.00------41.02-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Rhythm Biosciences Ltd52.28k-6.86m15.41m----17.77--294.82-0.0301-0.03010.00020.00350.01141.911.02---148.83-134.13-199.13-168.97-4,946.29-1,807.84-13,115.47-9,433.231.58-1,750.400.1589---77.10-18.0116.56---5.69--
BTC Health Ltd16.36k1.06m15.56m1.0013.913.1514.74950.970.00350.00350.000050.01530.004------26.09-21.2227.32-22.60----6,450.37-3,306.65----0.00--23.38-38.62110.38------
Alterity Therapeutics Ltd268.42k-19.12m15.96m11.00--1.14--59.46-0.0052-0.00520.000070.00260.0115--0.1307---82.18-56.58-103.97-66.91-----7,124.45-22,925.08----0.0114--1,532.7319.85-38.51---4.01--
Biotron Ltd1.65m-3.44m18.95m4.00------11.52-0.0038-0.00380.0018-0.00030.7108-------148.49-77.12-234.15-92.61-120.34-127.14-208.89-238.85--------14.948.931.61------
Invion Ltd3.74m-5.63m20.30m8.00--1.37--5.42-0.0009-0.00090.00060.00220.217--2.65---32.63-19.46-34.28-20.50-----150.33-70.20----0.00---9.54-0.7235-248.51--171.96--
Tryptamine Therapeutics Ltd1.21m-4.32m21.78m----3.24--18.04-0.0162-0.01620.00390.00620.2368-------84.69---120.26-------357.70-----21.620.00--------------
LBT Innovations Limited1.31m-3.74m23.13m17.00--13.20--17.66-0.0032-0.00320.0010.00110.17120.09592.52---48.89-34.86-78.03-38.5388.63---285.50-513.872.56-12.080.5686---39.04-14.7183.40---69.50--
Bioxyne Ltd9.33m-12.80m26.61m16.00--7.38--2.85-0.007-0.0070.00640.00180.76463.7810.33---106.39-56.02-134.91-72.4636.4440.00-139.14-85.521.18-40.410.0526--80.7034.32-559.75--50.56--
Amplia Therapeutics Ltd4.44m-4.50m27.21m1.00--1.73--6.13-0.0226-0.02260.02220.05720.2647--2.05---26.86-25.13-32.90-27.42-----101.48-206.74----0.122--286.42144.8127.86---6.91--
Tissue Repair Ltd548.09k-4.14m29.02m----1.61--52.95-0.0684-0.06840.00910.29830.02620.001.22---19.81-24.20-20.72-25.29100.00---755.00-10,570.1414.34--0.00--4,842.86--0.8698------
Noxopharm Ltd2.41m-3.58m29.22m1.00k--5.32--12.14-0.0086-0.00860.00820.01880.2847--2.00---42.31-43.24-48.67-52.58-----148.64-170.07---------60.33-9.3776.24------
Prescient Therapeutics Ltd687.57k-8.24m32.21m3.00--1.78--46.85-0.0102-0.01020.00090.02240.0284--3.31---33.97-28.85-37.31-30.66-----1,198.14-2,096.39---288.970.018--49.7756.99-17.61------
Cynata Therapeutics Ltd417.71k-9.74m34.33m0.00--4.73--82.18-0.0543-0.05430.00230.04020.0305--1.85---71.18-39.49-81.37-42.96-----2,332.89-515.32----0.00--18.3816.5131.75------
Data as of Sep 20 2024. Currency figures normalised to Noxopharm Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
DFA Australia Ltd.as of 31 May 20230.000.00%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.